Mittie Doyle Sells 3,970 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Key Points

• Insider sale: Mittie Doyle sold 3,970 Avalo Therapeutics shares on April 6 at an average price of $18.01 for $71,499.70 under a pre‑arranged Rule 10b5‑1 plan, cutting her stake by 52.29% to 3,622 shares; she also sold 679 shares on April 1 and 25,492 shares on March 16.
• Stock and analyst backdrop: AVTX traded around $14.41 (12‑month range $3.39–$20.72) with a market cap of about $328.4M, and analysts are largely positive — consensus rating "Moderate Buy" with a consensus target of $44.20 and several raised price targets (e.g., HC Wainwright $40, Guggenheim $50).

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 3,970 shares of the firm's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the transaction, the insider directly owned 3,622 shares of the company's stock, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.00, for a total value of $10,864.00.
• On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.15, for a total value of $411,695.80.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock traded down $1.51 during mid-day trading on Wednesday, hitting $14.41. 1,576,942 shares of the company were exchanged, compared to its average volume of 588,728. Avalo Therapeutics, Inc. has a 12-month low of $3.39 and a 12-month high of $20.72. The company has a market capitalization of $328.40 million, a P/E ratio of -2.51 and a beta of 0.93. The business's 50 day simple moving average is $15.55 and its two-hundred day simple moving average is $16.10.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analysts' expectations of ($0.21) million. Equities research analysts predict that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

AVTX has been the topic of several analyst reports. HC Wainwright raised their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, March 25th. Mizuho raised shares of Avalo Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a "buy" rating and a $50.00 price objective on the stock. BTIG Research restated a "buy" rating and set a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Finally, Wall Street Zen raised shares of Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Sunday, March 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BIT Capital GmbH acquired a new stake in shares of Avalo Therapeutics in the third quarter worth approximately $25,000. PFS Partners LLC increased its position in Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company's stock worth $36,000 after purchasing an additional 1,000 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics during the third quarter worth approximately $143,000. Boothbay Fund Management LLC purchased a new position in Avalo Therapeutics during the second quarter worth approximately $56,000. Finally, Jump Financial LLC acquired a new position in shares of Avalo Therapeutics in the 4th quarter valued at $238,000. Institutional investors and hedge funds own 87.06% of the company's stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.